Lyon Sarcoid Uveitis Cohort (LUCS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03863782|
Recruitment Status : Recruiting
First Posted : March 5, 2019
Last Update Posted : March 21, 2022
Sarcoidosis is a systemic disease with unknown etiology. Chronicity of the disease is observed in 1/3 of cases. Five percent of the affected patients are expected to die due to pulmonary worsening. After pulmonary complications, ocular complications are one of the most frequent complications. In hospital setting 2 to 15% of patients who come for initial uveitis diagnosis are after examination due to Sarcoidosis. Sarcoidosis diagnosis is based on paraclinical exams (biological, radiography) and histological confirmation. Corticotherapy (local or general) is usually used to cure sarcoid uveitis. In case of failure immunosuppressor or anti-tumor necrosis factor (TNF) can be used. In 10% of cases ocular symptoms including blindness are observed. Only treatment administrated quickly after diagnosis of sarcoid uveitis can prevent from ophthalmologic complications.
The main objective of the Lyon Sarcoid Uveitis Cohort study is to analyze the relevance of the paraclinical exam for sarcoid uveitis diagnosis, and to define a better visual and extra-ophthalmologic prognosis and describe the therapeutic practice in our Department.
This study is proposed to all patients diagnosed with Sarcoid uveitis with a histological confirmation and referred to the internal medicine department of the Croix-Rousse hospital, Lyon, France, for etiologic diagnosis or treatment.
|Condition or disease||Intervention/treatment|
|Sarcoid Uveitis||Other: No intervention|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Lyon Sarcoid Uveitis Cohort|
|Actual Study Start Date :||January 1, 2016|
|Estimated Primary Completion Date :||January 1, 2023|
|Estimated Study Completion Date :||January 1, 2023|
The cohort is composed by patients diagnosed or treated for sarcoid uveitis in the departement for Internal Medicine, Croix Rousse Hospital, Lyon, France.
Other: No intervention
No specific intervention. Collection of clinical data
- Clinical evolution (persistence or resolution) evaluated by gradation of SEN [ Time Frame: At one year after diagnosis ]Persistence of disease is characterized by persistence of intraocular inflammation evaluated by gradation of SEN. (reference: A Standardization Grading System for Scleritis . Ophthalmology 2011 Apr;118(4):768-71). SEN score ranges from 0 to 5 (resolution = score 0 and persistence = score >0)
- Anatomic characteristic of sarcoid uveitis [ Time Frame: At inclusion visit ]The anatomic characteristics of sarcoid uveitis will be described: anterior or posterior inflammation of greater rings of iris, ciliary margin of iris
- Corticoid treatment duration [ Time Frame: At one year after diagnosis ]Treatment used to cure uveitis: duration of corticotherapy treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03863782
|Contact: Pascal SEVEfirstname.lastname@example.org|
|Contact: Nora Martelemail@example.com|
|Hospices Civils de Lyon||Recruiting|
|Contact: Pascal SEVE firstname.lastname@example.org|